FIGURE 2.

Consistency of response by number of months for (a) all patients (n = 100). (b) episodic migraine patients (n = 54) and (c) chronic migraine patients (n = 46). Proportions of patients with, respectively, ≥30%, ≥50%, ≥75% and 100% reduction in migraine days compared to the baseline month, are shown, presented by number of months (cumulative) with this response. A month is defined as 28 days. For patients who discontinued erenumab before 6 months, the months without medication were counted as <30% reduction.